References
- Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-31
- Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced nonsmall cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6
- Carmichael J, Possinger K, Phillip P, Bey kirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcita bine. J Clin Oncol 1995;13:2731-6
- Nelson R, Tarassoff P. Dyspnoea with ge mcitabine is commonly seen, often disease related, transient and rarely severe. Eur J Cancer 1995;31(A) (Suppl 5):S197-8
- Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from tre atment with gemcitabine. Cancer 1997;80:286-91
- Vander Els NJ, Miller V. Successful tre atment of gemcitabine toxicity with a briefcourse of oral corticosteroid therapy. Chest 1998;114:1779-81
- Marruchella A, Fiorenzano G, Merizzi A, Rossi S, Chiodera PL. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998;11:504-6
- Rosado MF, Kett DH, Schein RMH, Baraona FJ, Sridhar KS. Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 2002;25:31-3
- Boicelle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity : CT features. J Comput Assit Tomogr 2000;24:977-80
- Anderson BS, Luna MA, Mario A, Yee C, Hui KH, Keating MJ, et al. Fatal pulmonary failure complicating high-dose cytosine arabi noside therapy in acute leukemia. Cancer 1990;65:1079-84
- Anderson BS, Cogan BM, Keating MJ, Estey EH, McCreadie KB, Freireich EJ. Subacute pulmonary failure complicating therapy with high dose ara-C in acute leukemia. Cancer 1985;56:2181-4
- Foucher P, Biour M, Blayac JP, Godard P, Sgro C, Kuhn M, et al. Drugs that mayinjure the respiratory system. Eur Respir J 1997;10: 265-279
- Haupt HM, Hutchins GM, Moore GW. Ara-C Lung: noncardiogenic pulmonary edema com plicating cytosine arabinoside therapy of leukemia. Am J Med 1981;70:256-61